BAILARD, INC. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.

Quarter-by-quarter ownership
BAILARD, INC. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q1 2024$1,071,216
-12.4%
15,480
-9.4%
0.03%
-16.7%
Q4 2023$1,223,270
+39.1%
17,080
+1.2%
0.04%
+24.1%
Q3 2023$879,279
-17.7%
16,8800.0%0.03%
-21.6%
Q2 2023$1,068,842
+27.5%
16,880
+9.0%
0.04%
+23.3%
Q1 2023$838,242
-47.3%
15,480
-48.5%
0.03%
-50.8%
Q4 2022$1,591,834
+6.3%
30,080
-6.5%
0.06%
-1.6%
Q3 2022$1,497,000
-18.5%
32,1800.0%0.06%
-13.9%
Q2 2022$1,837,000
-6.7%
32,1800.0%0.07%
+9.1%
Q1 2022$1,969,000
+16.9%
32,1800.0%0.07%
+22.2%
Q4 2021$1,684,000
-71.4%
32,180
-79.7%
0.05%
-73.3%
Q3 2021$5,897,000
-15.9%
158,180
-7.9%
0.20%
-16.5%
Q2 2021$7,009,000
+20.3%
171,7000.0%0.24%
+12.0%
Q1 2021$5,826,000
-20.8%
171,700
-25.8%
0.22%
-35.5%
Q4 2020$7,355,000
+117.2%
231,300
+75.2%
0.34%
+91.4%
Q3 2020$3,387,000
-6.4%
132,000
-6.4%
0.18%
-13.4%
Q2 2020$3,619,000141,0000.20%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 375,000$15,308,0005.42%
SILVERARC CAPITAL MANAGEMENT, LLC 113,258$4,623,0002.06%
Tri Locum Partners LP 150,783$6,155,0002.02%
COOPER/HAIMS ADVISORS, LLC 61,116$2,495,0001.64%
Vantage Consulting Group Inc 226,670$9,252,0001.61%
Nicholas Investment Partners, LP 598,261$24,421,0001.53%
Bellevue Group AG 3,609,919$147,357,0001.44%
GENERAL AMERICAN INVESTORS CO INC 350,804$14,320,0001.20%
Rhenman & Partners Asset Management AB 429,728$17,541,0001.19%
WASATCH ADVISORS LP 6,506,789$265,607,0001.08%
View complete list of INTRA CELLULAR THERAPIES INC shareholders